Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clovis Taps Into Rich "A" Round, Grabs Licensing Rights to Improved Gemcitabine

This article was originally published in The Pink Sheet Daily

Executive Summary

Clovis takes over work on Clavis's pancreatic cancer drug and will develop a companion test to target patients who fare poorly on Lilly's current standard of care.

You may also be interested in...



Clavis/Clovis' Pancreatic Cancer Drug Fails Despite Personalized Medicine Approach

The failure of Clavis Pharma's and Clovis Oncology's novel potential pancreatic cancer therapy CP-4126/CO-101 in the pivotal LEAP trial was associated with the surprising failure of a novel personalized medicine approach to treating the devastating disease.

Clovis Oncology Seeks $149.5 Million IPO

The Colorado cancer drug maker is seeking financing through the public capital markets.

Clovis Oncology Seeks $149.5 Million IPO

The Colorado cancer drug maker is seeking financing through the public capital markets.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel